COVID-19-EDV

COVID-19-EDV is an investigational prophylactic **SARS-CoV-2 vaccine** developed by **EnGeneIC** using its **EDV nanocell platform**. Public descriptions indicate the product is built from EnGeneIC Dream Vector nanocells loaded with three functional molecular components: one that drives **SARS-CoV-2 spike protein** production within the nanocell to induce an antibody response, a second intended to activate antiviral immune cells, and a third intended to improve antibody affinity and neutralization breadth. The program was positioned especially for populations with impaired immunity, and entered **Phase 1** clinical testing in Australia in healthy adults. The precise molecular composition and validated human mechanism remain only partially disclosed in public sources, so the vaccine is best characterized as an experimental nanocell-based COVID-19 vaccine designed to elicit both humoral and cellular antiviral immunity.

Other names

EnGeneIC Dream Vectornanocellular anti-COVID-19 vaccine